Insights+: The US FDA New Drug Approvals in September 2020

The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 85 novel products so far in 2020, including 6 in Sept 2020. Additionally, last year…

BySenior EditorOctober 15, 2020

THOUGHTSPOT

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

With the race to develop an effective vaccine becoming intense, how has the coronavirus pandemic changed the pharmaceutical industry, and what can we expect in the long- and short-term? Let's see. The year 2020, and the new decade as a whole, has definitely got off to the worst possible start and we have a pandemic…

BySenior EditorSeptember 28, 2020

TOP 20

Top 20 Oncology Companies by Total Products of 2019

To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However- despite robust levels of pipeline activity- oncology remains a challenging area for research…

ByPrince GiriSeptember 24, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of July 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Cadila expanded its footprints in India with the launch of its two biosimilars Bevaro (bevacizumab, biosimilar) and Ritucad (rituximab, biosimilar) Our team at PharmaShots has summarized 9 key events of the biosimilar space of July 2020 1. Samsung…

BySenior EditorAugust 7, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – July 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…

BySenior EditorJuly 31, 2020

TOP 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

ByPrince GiriJuly 17, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the…

BySenior EditorJuly 3, 2020

INSIGHTS+

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased…

BySenior EditorJune 1, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorMay 29, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of April 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…

BySenior EditorMay 8, 2020

Insights+: The US FDA New Drug Approvals in September 2020

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

Top 20 Oncology Companies by Total Products of 2019

Insights+ Key Biosimilars Events of July 2020

Insights+: COVID-19 Healthcare News Monthly Updates – July 2020

Top 20 Prescription Drugs Based on 2019 Revenue

Insights+ Key Biosimilars Events of June 2020

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Insights+ Key Biosimilars Events of April 2020

Contact US

FOLLOW US